The induced pluripotent stem cell (iPSC) was first described more than 10 years ago and is currently used in various basic science and clinical research fields. The aim of this report is to examine the trends in research using iPSCs over the last 10 years. The 2006-2016 PubMed database was searched using the MeSH term ''induced pluripotent stem cells.'' Only original research articles were selected, with a total of 3323 articles. These were classified according to research theme into reprogramming, differentiation protocols for specific cells and/or tissues, pathophysiological research on diseases, and discovery of new drugs, and then the trends over the years were analyzed. We also focused on 232 research publications on the pathophysiological causes of diseases and drug discovery with impact factor (IF; Thomson Reuters) of six or more. The IF of each article was summed up by year, by main target disease, and by country, and the total IF score was expressed as trends of research. The trends of research activities of reprogramming and differentiation on specific cells and/or tissues reached maxima in 2013/ 2014. On the other hand, research on pathophysiology and drug discovery increased continuously. The 232 articles with IF ‡6 dealt with neurological, immunological/hematological, cardiovascular, and digestive tract diseases, in that order. The majority of articles were published from the United States, followed by Japan, Germany, and United Kingdom. In conclusion, iPSCs have become a general tool for pathophysiological research on disease and drug discovery.
Introduction
The first report that described induced pluripotent stem cells (iPSCs) was published more than 10 years ago. 1 In the early days, iPSCs could be handled only by topranking researchers, but they are currently available to almost all researchers and used in various types of research fields. The aim of this research article is to investigate the phase transition of iPSC-based research.
One of the advantages of iPSCs compared with other kinds of stem cells is the availability to create cell models for diseases and based on that the pathophysiological research of diseases and drug discovery can be developed by reprograming cells from diseased patients and inducing cell differentiation suitable for evaluation. 2 In this study, we searched and selected research articles that described work using iPSCs and were published between 2006 and recent years from the PubMed database and classified these publications according to their themes into reprogramming, differentiation protocols for specific cells and/or tissues, pathophysiological research of diseases, discovery of new drugs, and cell therapy, and then the trends over the years were analyzed. We also focused on the fields of pathophysiological research of diseases and drug discovery. In this regard, we used the impact factor (IF) score provided by Thomson Reuters. The IF score represents the average number of citations per article in a journal for 2 years since its publication and is used as an index to evaluate the journal. While IF itself does not directly reflect the scientific importance of the article, it has also been used, in general, as an index for evaluation of individual articles published in the journal, and the total IF score obtained by simply summing up a range of IF values has been used for relative comparison with others (e.g., Cao et al. 3 ). It is thought that total IF score represents the expected score of the total number of citations in the range of those articles. Thus, in this study, we decided to use it as a rough index representing the quality · quantity of a given range of publication to evaluate trend of research on a particular main target disease or by nation.
Methods
To investigate the research trend of iPSCs, we searched the PubMed database for publications published between 2006 and 2016 (*August) using the MeSH term ''induced pluripotent stem cells.'' However, since the term ''induced pluripotent stem cells'' was applied only after 2010, we also manually selected articles among those published between 2006 and 2009 and identified in the database with the search terms ''induced pluripotent stem cells [All Fields]'' OR ''pluripotent stem cells [MeSH Major Topics] .'' To identify only original research articles, nonoriginal articles such as reviews, commentaries, news, and historical articles were excluded from the resultant article pool. Due to incomplete exclusion, some publications were deleted manually by further inspection of the articles. Articles that did not contain abstracts in the PubMed database were also excluded because it was impossible to evaluate such articles at a later stage. The 3323 indexed articles were later classified according to their themes into reprogramming, differentiation protocols for specific cells and/or tissues, pathophysiological research of diseases, discovery of new drugs, and cell therapy according to the following criteria:
(a) Reprogramming to iPSCs: all research articles related to reprogramming, such as genes, host cells, transfection methods, mRNA analysis, media, and feeder cells. Among these articles, we also selected (a¢) iPSC preparation protocols. Among (a), research articles that focused on iPSC preparation protocols were especially selected.
(b) Differentiation protocols for specific cells and/or tissues and research: differentiation research using iPSCs, including protocols for specific cells and/or tissues and related research. (c) Pathophysiological research of diseases: included research articles that used patient-derived and/ or disease-specific iPSCs in the title and/or abstract. (d) Drug discovery: research articles that focused on applications to the so-called conventional drug discovery. Articles with only suggestion or without description of compound evaluation were excluded. (e) Cell therapy: included research articles on application of iPSCs for cell therapy. Articles on antigenicity of iPSCs were also included in this category. In addition, when the article was considered to fall under multiple themes, we allowed up to two duplicates.
We obtained the IF from the Journal Citation Reports provided by Thomson Reuters, used the 2015 version data, indexed the IF score given to the individual journal to the corresponding article, and throughout this work, we handled them as IF scores of individual articles. In this work, the Journal Citation Reports covered about 93% of resultant articles selected from PubMed-listed journals. Journals that were not listed on the Journal Citation Reports were marked with IF = 0, about half of which were published in languages other than English.
The development stage was classified into three categories; basic research, applied research (drug screening or medicinal pharmacology), and translational research (preclinical and clinical tests). Articles were also classified according to countries of the corresponding author.
Results
To investigate the phase transition of iPSC-based research, we surveyed articles listed in the PubMed database. First, from the articles published between 2006 and 2016 (*August), we selected 3323 articles using the MeSH Term ''induced pluripotent stem cells,'' excluding nonoriginal research articles, such as reviews. Figure 1A shows the number of articles classified according to their themes (reprogramming, differentiation, pathophysiological research of diseases, drug discovery, and cell therapy) and publication year (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) . Figure 1B Taking into consideration the above findings, we decided to focus on articles on pathophysiological research and drug discovery based on the growth trend in their numbers in recent years. Because the number of articles on discovery of new drugs was small and the theme of most such articles overlapped with pathophysiological research, we decided to combine both sets of articles into one group for better analysis. For convenience, we divided the pool of articles to be analyzed into nearly three equal parts in IF order. Its boundary between the top 1/3 and the middle 1/3 was IF = 6. The top 1/3 could contain articles with more expected number of citations, in other words, larger influence to produce research trends than the middle 1/3 and the bottom 1/3. In this way, we thought that selecting relatively large influential articles is consistent with our purpose of investigating the research trend with saving labor. So, we decided to analyze only the top 1/3 articles with IF of ‡6 hereafter. As a result, our pool of articles to be analyzed was narrowed down to 39% actually, yet it covered *73% of the total IF score of a whole. Analysis based on the development stage Among articles with IF of ‡6 classified with the pathophysiological research and/or drug discovery theme, those on neurological diseases were the most frequent, followed by those on cardiovascular, immunological/ hematological, and digestive tract diseases. Articles on the urinary tract, respiratory, and ophthalmological diseases were the least. These articles were further classified into three categories; basic, applied, and translational research, according to the development stage. Surprisingly, no articles were published on translational research (preclinical and clinical), whereas several dealt with research that focused mainly on disorders of the cardiovascular and nervous systems (Table 1 ). In the cardiovascular area, the six applied research articles dealt with the topics of long QT syndrome, 4-6 cardiotoxicity, 7 drug-induced arrhythmias, 8 and catecholaminergic polymorphic ventricular tachycardia. 9 In the neurological disease field, six applied research articles dealt with Parkinson's disease, 10 ,11 Down's syndrome, 12 familial dysautonomia, 13 amyotrophic lateral sclerosis (ALS), 14 and paclitaxelinduced sensory peripheral neuropathy. 15 Analysis based on the publication year Figure 2 shows the number of articles with IF of ‡6 stratified according to body systems and publication year. The number of articles on cardiovascular, neurological, and immunological/hematological diseases increased steadily since 2010. Research on liver, which is important as it evaluates toxicity, started to increase since 2014.
Interestingly, the pattern of total IF according to the publication year was similar to that of number of publications (not shown). Figure 3 shows the results of analysis of the number of publications with IF of ‡6 by country. The highest number (n = 161) of articles were published by scientists from the United States. The number of publications on iPSCs from the United States far exceeded those from Japan, which came second, followed by Germany and the United Kingdom. Other countries included Israel, China, South Korea, and France. 
Analysis based on country of corresponding author
a The sum does not always match up to ''Sum'' because it counts articles spanning multiple disease areas in duplicate. Figure 4 shows the share of total IF score in pathophysiological research/drug discovery articles with IF of ‡6 according to diseases of body systems. Analysis of the total IF scores, that is, the mass (quality · quantity) of research, showed the following order: neurological diseases > cardiovascular diseases > immunological/ hematological diseases > digestive tract diseases (Fig. 4) . The mass of research on neurological diseases was twice as large (top rank) as that on cardiovascular diseases (second rank) and about 10 times that of the digestive tract diseases (fourth rank), a trend almost similar to that of numbers of publications.
The pattern of ranking of nations according to total IF score ( Fig. 5) was almost same as the number of publications shown in Figure 3 that of Japan, which ranked the second. South Korea, which ranked seventh by the number of research articles, moved down to the 10th place on total IF score. Further analysis of the research area according to country (Fig. 6) showed that research work involving iPSCs in the United States focused on extremely wide variety of neurological diseases (e.g., Parkinson's disease, 10, 11, [16] [17] [18] [19] [20] schizophrenia, [21] [22] [23] [24] [25] Alzheimer's disease, [26] [27] [28] [29] [30] and Huntington's disease), [31] [32] [33] [34] [35] 7, 8, 52 and digestive tract diseases (e.g., a1-antitrypsin deficiency [53] [54] [55] and drug discovery). [56] [57] [58] Furthermore, the United States made significant pioneering contribution to iPSC-based research on diabetes mellitus [59] [60] [61] and progeria, 40, [62] [63] [64] which were classified here as miscellaneous. Work from the United Kingdom also focused on neurological diseases (e.g., ALS), [65] [66] [67] while work from Germany focused on cardiovascular (e.g., arrhythmias) 9,68-70 and neurological diseases. [71] [72] [73] [74] [75] Publications by Japanese scientists centered mostly on immunological/hematological [76] [77] [78] [79] [80] [81] and neurological diseases, 14, [82] [83] [84] [85] that is, resembling the pattern of the United States. Interestingly, Japanese scientists published two articles on iPSCs in musculoskeletal diseases, 86, 87 which were similar to the numbers of respective articles published by the American and British scientists. It is noteworthy that Japan has so far not published any article on iPSCs in cardiovascular diseases. It should be noted, however, that these are results using only original research articles in relatively large influential journals, that is, those with IF ‡6.
Discussion
In their study on research trends on human embryonic stem cells (ESCs) and iPSCs, Kobold et al. 88 evaluated the relevance between studies on both cells in scientific articles published up to 2013. They compared the quality of ESC/iPSC research by calculating the average number of citations per article using Scopus instead of IF. In the present study, we classified articles on iPSCs per main theme without limitation to human iPSCs, evaluated the quality x quantity mass of each theme using total IF score, in addition to the number of articles, and further investigated worldwide research trends, focusing on research on the pathophysiological mechanisms of various diseases and on drug discovery.
We selected articles from the PubMed database published from 2006, when Takahashi and Yamanaka   1 reported the first iPSC preparation, to the end of August 2016 and analyzed the data.
The results showed that the number and total IF score of articles on iPSC-related reprogramming and differentiation research increased steadily from 2006 to 2013, reached maximum levels in 2013, and then started to decrease gradually between 2014 and 2015. On the other hand, the number of pathophysiology research and drug discovery articles increased continuously and forereached those of reprogramming and differentiation research in 2015. This tendency was remarkably evident on the total IF plot (Fig. 1B) .
How can we interpret the above data? It is likely that most of the elemental technologies necessary for the preparation of iPSCs and differentiation of iPSCs into the target cells/tissues were investigated and defined in the early days of iPSC research and that research centered on practical and clinical issues, such as pathophysiological mechanisms of diseases and discovery of new drugs (which was developed applying the above technologies), is now entering the maturation stage. In this regard, we performed meta-analysis of the articles dealing with pathophysiological causes of diseases/drug discovery with IF of ‡6. It allowed narrowing the number of articles down to the top 39% with IF, which still covered *73% of the total IF score of a whole.
What about publications on the development stage? Although the number of articles on pathophysiological studies of diseases/drug discovery rose obviously in recent years, the majority of such reports are still at the basic research level, for example, exploring the relationship between gene mutation and disease status, and only a few studies reported concrete results, e.g., practical drug screening and/or discovering new candidate compounds. 8, 11, 13, 58, 89 Among these, we found six applied research articles in the field of cardiovascular and neurological diseases, where the needs of pharmaceutical companies had been high, although it was difficult to obtain human samples.
One article on sensory peripheral neuropathy describing the side effects of paclitaxel 15 is probably the most practical and clinically oriented report so far, although the study was not a new drug development study, but rather a postmarketing study. This is in contrast to the lack of publications dealing with applications in the field of immunology/hematology. It is possible that this paucity of research is related to the strategy to develop cell therapy using genome editing, instead of conventional drug screening.
Careful analysis of the published articles based on the year of publication identified sufficient number of articles on cardiovascular diseases, neurological diseases, and immunological/hematological diseases published on regular basis dating back before 2010. Interestingly, the number of articles on neurological diseases increased steeply since 2012; we think that it was, in part, related to the progress and availability of genome editing technology, such as ZFN, TALEN, and CRISPR/Cas 9. On the other hand, the number of published articles on the digestive system has also increased in recent years. The main reason suggested is that pharmaceutical companies needed the establishment of cell models reproducing human liver for drug discovery. Analysis of the countries at which iPSC-based research studies were conducted showed that 161 articles with IF of ‡6 (representing 63% of the selected publications on the pathophysiology of diseases) were published by US scientists. The second group consisted of Japan, Germany, and the United Kingdom, but the combined number of publications with IF of ‡6 from these three countries was less than half of those from the United States.
A close look at the research area by country showed that research from the United States accounts for the majority of publications on cardiovascular, neurological, immunological/hematological, respiratory, and ophthalmological diseases, although there were only a few on musculoskeletal, gastrointestinal, and urological diseases (Fig. 7) . In addition, although they were classified under miscellaneous, the United States also majored in iPSC-based publications on diabetes and progeria. Japan, which held the second rank in the number of articles with IF of ‡6, published relatively large number of research articles on immunological/ hematological and neurological diseases. While the number of articles on immunological/hematological diseases showed a presence, those on neurological diseases were unremarkable despite ranking third in the number of publications, compared with the United States. Interestingly, about 25% of the total numbers of articles published on musculoskeletal and digestive diseases were authored by Japanese researchers. However, Japan has so far not published studies on the cardiovascular system with IF of ‡6 in peer-reviewed journals.
Germany, which ranked third in the number of articles with IF of ‡6 on iPSC-based research, ranked second in publications on cardiovascular and respiratory systems, while the United Kingdom, which ranked fourth in the number of articles with IF of ‡6, had the second highest number of publications in the musculoskeletal and digestive fields. Israel, which ranked fifth in the number of published articles, mainly published work on cardiovascular diseases. Furthermore, although Japan ranked second by both the number of articles and total IF score, it is necessary to keep in mind that Japan's position slips to third place when the publications of Germany, France, Spain, and other EU countries are grouped together.
Research projects on the pathophysiology of diseases/drug discovery are closely related to major patient-derived iPSC bank projects in major countries around the world. Genomics Resource (NRGR) and the state-sponsored stem cell research institutes, such as California Institute for Regenerative Medicine (CIRM) and The New York Stem Cell Foundation (NYSCF), produce and deposit patient-derived iPSC lines that focus on various diseases and use them to encourage various research activities on the pathophysiology of diseases and drug discoveries. Looking to Europe, industry-academiclinked patient-derived iPSC bank projects such as the Human Induced Pluripotent Stem Cell Initiative (HipSci) and the European Bank for induced pluripotent Stem Cells (EBiSC) are currently very active. A typical example of a recent article on pathophysiological research of diseases reported identification of the target causative mutation through genetic analysis and the response of cells as detected by in vitro techniques. 34 Another study provided more direct evidence for the disappearance of a phenotype following gene correction. 35 In this regard, most of the targeted diseases have so far been rare inheritable diseases. In most articles on immunological/hematological diseases, the combination of pathophysiological research on the disease and gene editing was frequently used to verify the preliminary findings of a series of gene therapy strategies that restored genes in iPSCs derived from the patients, differentiate them into target cells, and infuse them later into the patients.
As discussed above, we believe that research on the pathophysiological mechanisms of diseases can be fruitful when iPSC technology is combined with cell analysis and genome editing. Meanwhile, a recent project named Next Gen studies funded by the National Heart, Lung, and Blood Institute (NHLBI) has tied up with cohort studies and started research on patient-derived iPSCs, which also covers common diseases. This is also a very interesting new clinical research venture.
Conclusion
Thus, our analysis revealed that the research trend of iPSCs has shifted from research targeting the iPSC itself as reprogramming and differentiation studies to practical application research utilizing iPSC technology as a tool for pathophysiological mechanism of disease and discovery of new drug. It is expected that further steps will be advanced in the future to realize the treatment of human diseases. We hope that the results of research projects currently being developed and conducted around the world can help as many patients as possible.
